Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients
Authors' conclusion
A simple ceramide- and phospholipid-based risk score can efficiently predict residual CVD event risk in patients with coronary artery disease.
Study context
- Population
- Patients with atherosclerotic CHD
- Outcome
- CVD mortality
Methodological detailsthree independent cohorts, derivation in WECAC, validation in LIPID and KAROLA, Ceramides and phosphatidylcholines (PCs) analysed by liquid chromatography-mass spectrometry (LC-MS)
- Three independent cohorts
- Derivation in WECAC, validation in LIPID and KAROLA
- Ceramides and PCs analysed by LC-MS
Performance
As reported in the abstract
CVD mortality, ceramide-phospholipid risk score (multiadjusted HR per SD)
Hazard ratio per SD (95% CI)
WECAC
1.44(1.28–1.63)
LIPID
1.47(1.34–1.61)
KAROLA
1.69(1.31–2.17)
Per SD, as printed
Further findings
Cardiovascular disease (CVD) mortality, risk score combined with high-sensitivity troponin T
| HR (CI) | ||
|---|---|---|
| WECAC | 1.63 (1.44–1.85) | |
| KAROLA | 2.04 (1.57–2.64) | |
| 0.20.5125Hazard ratio (log scale) |
| Outcome | Values |
|---|---|
| Discrimination for CVD death, risk score + sex and age (WECAC) | WECAC C-statistic 0.76 |
Comparison with published secondary-prevention CVD risk models
- Comparable and synergistic predictive performance
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients. Eur Heart J. Published 18 June 2019. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →